News & Events

CAMBRIDGE, Mass., May 15, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders.

At the meeting, stockholders approved the amendment to Vertex's Articles of Organization increasing the number of its authorized shares of common stock from 200 million to 300 million, the amendment to Vertex's 2006 Stock and Option Plan adding an additional 6.6 million shares to the Stock and Option Plan, and the amendment to Vertex's Employee Stock Purchase Plan adding an additional 2 million shares to that Plan. Stockholders also approved the ratification of Vertex's Independent Registered Public Accounting Firm.

In addition, stockholders re-elected all three director nominees at the meeting. Each of the director nominees, Stuart J. M. Collinson, Eugene H. Cordes and Matthew W. Emmens, received a majority of votes cast. Their terms will expire at the 2011 Annual Meeting of Stockholders.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex's press releases are available at www.vrtx.com.

(VRTX-GEN)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-444-6108
Senior Director, Strategic Communications
or
Lora Pike, 617-444-6755
Manager, Investor Relations

Copyright Business Wire 2008

News Provided by COMTEX